Expert guidelines for the management of alport syndrome and thin basement membrane nephropathy

Journal of the American Society of Nephrology

Volumn 24, Issue 3, 2013, Pages 364-375

  Savige, Judy ^a   Gregory, Martin ^b   Gross, Oliver ^c   Kashtan, Clifford ^d   Ding, Jie ^e   Flinter, Frances ^f  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e PEKING UNIVERSITY FIRST HOSPITAL   (China)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METALLOPROTEINASE INHIBITOR; PLACEBO; VASOPEPTIDASE INHIBITOR;

ALPORT SYNDROME; CLINICAL FEATURE; COL4A3 GENE; COL4A4 GENE; COL4A5 GENE; GENE; GENE MUTATION; GENETIC COUNSELING; GENETIC SCREENING; HUMAN; KIDNEY DISEASE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; STEM CELL TRANSPLANTATION; THIN BASEMENT MEMBRANE NEPHROPATHY;

EID: 84874616744     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012020148     Document Type: Review

References (69)

1. Hogg RJ, Harris S, Lawrence DM, Henning PH, Wigg N, Jureidini KF: Renal tract abnormalities detected in Australian preschool children. J Paediatr Child Health 34: 420-424, 1998 (Pubitemid 28481725)
2. Ritchie CD, Bevan EA, Collier SJ: Importance of occult haematuria found at screening. Br Med J 292: 681-683, 1986
3. Savige J, Rana K, Tonna S, Buzza M, Dagher H, Wang YY: Thin basement membrane nephropathy. Kidney Int 64: 1169-1178, 2003 (Pubitemid 37153781)
4. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG: Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 348: 2543-2556, 2003 (Pubitemid 36706542)
5. Hasstedt SJ, Atkin CL: X-linked inheritance of Alport syndrome: Family P revisited. Am J Hum Genet 35: 1241-1251, 1983 (Pubitemid 14201175)
6. Persson U, Hertz JM, Wieslander J, Segelmark M: Alport syndrome in southern Sweden. Clin Nephrol 64: 85-90, 2005 (Pubitemid 41079003)
7. Savige J, Ratnaike S, Colville D: Retinal abnormalities characteristic of inherited renal disease. J AmSocNephrol 22: 1403-1415, 2011
8. Gubler M, Levy M, Broyer M, Naizot C, Gonzales G, Perrin D, Habib R: Alport's syndrome. A report of 58 cases and a review of the literature. Am J Med 70: 493-505, 1981 (Pubitemid 11153813)
9. Yoshioka K, Hino S, Takemura T, Maki S, Wieslander J, Takekoshi Y, Makino H, Kagawa M, Sado Y, Kashtan CE: Type IV collagen alpha 5 chain. Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody. Am J Pathol 144: 986-996, 1994
10. Barker DF, Hostikka SL, Zhou J, Chow LT, Oliphant AR, Gerken SC, Gregory MC, Skolnick MH, Atkin CL, Tryggvason K: Identification of mutations in the COL4A5 collagen gene in Alport syndrome. Science 248: 1224-1227, 1990
11. Mochizuki T, Lemmink HH, Mariyama M, Antignac C, Gubler MC, Pirson Y, Verellen-Dumoulin C, Chan B, Schröder CH, Smeets HJ, et al: Identification of mutations in the alpha 3(IV) and alpha 4(IV) collagen genes in autosomal recessive Alport syndrome. Nat Genet 8: 77-81, 1994 (Pubitemid 2122272)
12. Feingold J, Bois E, Chompret A, Broyer M, Gubler MC, Grünfeld JP: Genetic heterogeneity of Alport syndrome. Kidney Int 27: 672-677, 1985 (Pubitemid 15092195)
13. van der LoopFT,Heidet L,Timmer ED, van den Bosch BJ, Leinonen A, Antignac C, Jefferson JA, Maxwell AP, Monnens LA, Schröder CH, Smeets HJ: Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation. Kidney Int 58: 1870-1875, 2000
14. Cosio FG, Falkenhain ME, Sedmak DD: Association of thin glomerular basement membrane with other glomerulopathies. Kidney Int 46: 471-474, 1994 (Pubitemid 24253055)
15. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Verellen C, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Krejcova S, CarvalhoMF, Saus J, Antignac C, Smeets H, Gubler MC: X-linked Alport syndrome: Natural history in 195 families and genotype-phenotype correlations in males. J Am Soc Nephrol 11: 649-657, 2000 (Pubitemid 30171874)
16. Hertz JM, Thomassen M, Storey H, Flinter F: Clinical utility gene card for Alport syndrome Eur J Hum Genet 20: 6, 2012
17. Gubler MC: Diagnosis of Alport syndrome without biopsy? Pediatr Nephrol 22: 621-625, 2007 (Pubitemid 46691515)
18. Jais JP, Knebelmann B, Giatras I, De Marchi M, Rizzoni G, Renieri A, Weber M, Gross O, Netzer KO, Flinter F, Pirson Y, Dahan K, Wieslander J, Persson U, Tryggvason K, Martin P, Hertz JM, Schröder C, Sanak M, Carvalho MF, Saus J, Antignac C, Smeets H, Gubler MC: X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: A "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14: 2603-2610, 2003 (Pubitemid 37169346)
19. Tan R, Colville D, Wang YY, Rigby L, Savige J: Alport retinopathy results from "severe" COL4A5 mutations and predicts early renal failure. Clin J AmSocNephrol 5: 34-38, 2010
20. Rumpelt HJ, Langer KH, Schärer K, Straub E, Thoenes W: Split and extremely thin glomerular basement membranes in hereditary nephropathy (Alport's syndrome). Virchows Arch A Pathol Anat Histol 364: 225-233, 1974
21. GublerMC, Knebelmann B, Beziau A, Broyer M, Pirson Y, Haddoum F, Kleppel MM, Antignac C: Autosomal recessive Alport syndrome: Immunohistochemical study of type IV collagen chain distribution. Kidney Int 47: 1142-1147, 1995
22. van der Loop FT, Monnens LA, Schröder CH, Lemmink HH, Breuning MH, Timmer ED, Smeets HJ: Identification of COL4A5 defects in Alport's syndrome by immunohistochemistry of skin. Kidney Int 55: 1217-1224, 1999 (Pubitemid 29157117)
23. Copelovitch L, Kaplan BS: Is genetic testing of healthy pre-symptomatic children with possible Alport syndrome ethical? Pediatr Nephrol 21: 455-456, 2006
24. Hanson H, Storey H, Pagan J, Flinter F: The value of clinical criteria in identifying patients with X-linked Alport syndrome. Clin JAmSoc Nephrol 6: 198-203, 2011
25. King K, Flinter FA, Nihalani V, Green PM: Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome. Hum Genet 111: 548-554, 2002 (Pubitemid 36075087)
26. Hertz JM, Juncker I,Marcussen N:MLPA and cDNA analysis improves COL4A5 mutation detection in X-linked Alport syndrome. Clin Genet 74: 522-530, 2008
27. Wang F, Wang Y, Ding J, Yang J: Detection of mutations in the COL4A5 gene by analyzing cDNA of skin fibroblasts. Kidney Int 67: 1268-1274, 2005 (Pubitemid 40463103)
28. Tazon-Vega, B, Ars, E, Burset, M, Santin, S, Ruiz, P, Fernandez-Llama, P,Ballarin, J&Torra, R: Genetic testing for X-linked Alport syndrome by direct sequencing of COL4A5 cDNA from hair root RNA samples. Am J Kidney Dis 50: 257 e1-14, 2007
29. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M: Meta-analysis of genotypephenotype correlation in X-linked Alport syndrome: Impact on clinical counselling.Nephrol Dial Transplant 17: 1218-1227, 2002 (Pubitemid 34812066)
30. Kashtan CE: Alport syndrome and the X chromosome: Implications of a diagnosis of Alport syndrome in females. Nephrol Dial Transplant 22: 1499-1505, 2007 (Pubitemid 47073745)
31. Kashtan CE: Renal transplantation in patients with Alport syndrome. Pediatr Transplant 10: 651-657, 2006 (Pubitemid 44186284)
32. Savige J, ColvilleD:Opinion:Ocular features aid the diagnosis of Alport syndrome. Nat Rev Nephrol 5: 356-360, 2009
33. Proesmans W, Van Dyck M: Enalapril in children with Alport syndrome. Pediatr Nephrol 19: 271-275, 2004 (Pubitemid 38313009)
34. Kaito H, Nozu K, Iijima K, Nakanishi K, Yoshiya K, Kanda K, Przybyslaw Krol R, Yoshikawa N, Matsuo M: The effect of aldosterone blockade in patients with Alport syndrome. Pediatr Nephrol 21: 1824-1829, 2006 (Pubitemid 44741159)
35. Gross O, Licht C, Anders HJ, Hoppe B, Beck B, Tonshoff B, Hocker B, Wygoda S, Ehrich JH, Pape L, Konrad M, Rascher W, Dotsch J, Muller-Wiefel DE, Hoyer P, Knebelmann B, Pirson Y, Grunfeld JP, Niaudet P, Cochat P, Heidet L, Lebbah S, Torra R, Friede T, Lange K, Muller GA, Weber M: Early angiotensinconverting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy. Kidney Int 81:494-501, 2012
36. Gross O, Friede T, Hilgers R, Görlitz A, Gavénis K, Ahmed R, Dürr U: Safety and efficacy of the ACE-inhibitor ramipril in Alport syndrome: The double-blind, randomized, placebo-controlled, multicenter phase III EARLY PRO-TECT Alport trial in pediatric patients [published online July 1, 2012]. ISRN Pediatr doi:10.5402/2012/436046
37. Kashtan CE, Ding J, Gregory M, Gross O, Heidet L, Knebelmann B, Rheault M, Licht C: Clinical practice recommendations for the treatment of Alport syndrome: A statement of the Alport Syndrome Research Collaborative. Pediatr Nephrol 28:5-11, 2013
38. Koepke ML, Weber M, Schulze-Lohoff E, Beirowski B, Segerer S, Gross O: Nephroprotective effect of the HMG-CoA-reductase inhibitor cerivastatin in a mouse model of progressive renal fibrosis in Alport syndrome. Nephrol Dial Transplant 22: 1062-1069, 2007 (Pubitemid 46523419)
39. Zeisberg M, Khurana M, Rao VH, Cosgrove D, Rougier JP, Werner MC, Shield CF, Werb Z, Kalluri R: Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med 3: e100, 2006
40. Ninichuk V, GrossO, Reichel C, Khandoga A, Pawar RD, Ciubar R, Segerer S, Belemezova E, Radomska E, Luckow B, Perez de Lema G, Murphy PM, Gao JL, Henger A, Kretzler M, Horuk R,Weber M, Krombach F, Schlöndorff D, Anders HJ: Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease.J Am Soc Nephrol 16: 977-985, 2005 (Pubitemid 41710308)
41. Gross O, Koepke ML, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M: Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int 68: 456-463, 2005 (Pubitemid 43323100)
42. Sugimoto H, Mundel TM, Sund M, Xie L, Cosgrove D, Kalluri R: Bone-marrow-derived stem cells repair basement membrane collagen defects and reverse genetic kidney disease. Proc Natl Acad Sci U S A 103: 7321-7326, 2006 (Pubitemid 43727831)
43. Prodromidi EI, Poulsom R, Jeffery R, RoufosseCA, Pollard PJ, PuseyCD,CookHT: Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24: 2448-2455, 2006 (Pubitemid 44674305)
44. Kashtan CE, McEnery PT, Tejani A, Stablein DM: Renal allograft survival according to primary diagnosis: a report of the North American Pediatric Renal Transplant Cooperative Study. PediatrNephrol 9: 679-684, 1995 (Pubitemid 26003665)
45. Temme J, Kramer A, Jager KJ, Lange K, Peters F, Muller GA, Kramar R, Heaf JG, Finne P, Palsson R, Reisæter AV, Hoitsma AJ, MetcalfeW, Postorino M, Zurriaga O, Santos JP, Ravani P, Jarraya F, Verrina E, Dekker FW, GrossO:Outcomes ofmale patientswithAlport syndrome undergoing renal replacement therapy. Clin J AmSoc Nephrol 7: 1969-1976, 2012
46. Fleming SJ, Savage CO, McWilliam LJ, Pickering SJ, Ralston AJ, Johnson RW, Ackrill P: Anti-glomerular basement membrane antibody-mediated nephritis complicating transplantation in a patient with Alport's syndrome. Transplantation 46: 857-859, 1988 (Pubitemid 19013231)
47. Berardinelli L, Pozzoli E, Raiteri M, Canal R, Tonello G, Tarantino A, Vegeto A: Renal transplantation in Alport's syndrome. Personal experience in twelve patients. Contrib Nephrol 80: 131-134, 1990
48. Lemmink HH, Schröder CH, Monnens LA, Smeets HJ: The clinical spectrum of type IV collagen mutations.HumMutat 9: 477-499, 1997 (Pubitemid 27250812)
49. BrowneG, Brown PA, TomsonCR, Fleming S, Allen A, Herriot R, Pusey CD, Rees AJ, Turner AN: Retransplantation in Alport post-transplant anti-GBM disease. Kidney Int 65: 675-681, 2004 (Pubitemid 38130665)
50. Dagher H, Buzza M, Colville D, Jones C, Powell H, Fassett R,WilsonD, Agar J, Savige J: A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport's syndrome. Am J Kidney Dis 38: 1217-1228, 2001 (Pubitemid 34193106)
51. Rumpelt HJ: Hereditary nephropathy (Alport syndrome): Correlation of clinical data with glomerular basement membrane alterations. Clin Nephrol 13: 203-207, 1980
52. Temme J, Peters F, Lange K, Pirson Y, Heidet L, Torra R, Grunfeld JP, Weber M, Licht C, MüllerGA, GrossO: Incidence of renal failure and nephroprotection by RAAS inhibition in heterozygous carriers of X-chromosomal and autosomal recessive Alport mutations. Kidney Int 81: 779-783, 2012
53. Grünfeld JP, Noël LH, Hafez S, Droz D: Renal prognosis in women with hereditary nephritis. Clin Nephrol 23: 267-271, 1985 (Pubitemid 15059835)
54. Gross O, Weber M, Fries JW, Müller GA: Living donor kidney transplantation from relatives with mild urinary abnormalities in Alport syndrome: Long-term risk, benefit and outcome. Nephrol Dial Transplant 24: 1626-1630, 2009
55. Nakanishi K, Iijima K, Kuroda N, Inoue Y, Sado Y, Nakamura H, Yoshikawa N: Comparison of alpha5(IV) collagen chain expression in skin with disease severity in women with X-linked Alport syndrome. J Am Soc Nephrol 9: 1433-1440, 1998 (Pubitemid 28354553)
56. Meleg-Smith S,Magliato S, Cheles M, Garola RE, Kashtan CE: X-linked Alport syndrome in females. Hum Pathol 29: 404-408, 1998 (Pubitemid 28231907)
57. Eberhard OK, Kliem V, Offner G, Oldhafer K, Fangmann J, Pichlmay R,KochKM, Brunkhorst R: Assessment of long-term risks for living related kidney donors by 24-h blood pressure monitoring and testing for microalbuminuria. Clin Transplant 11: 415-419, 1997 (Pubitemid 27460437)
58. Kashtan CE: Women with Alport syndrome: risks and rewards of kidney donation. Nephrol Dial Transplant 24: 1369-1370, 2009
59. Steele DJ, Michaels PJ: Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 40-2004 -A 42-year-old woman with long-standing hematuria. N Engl JMed 351: 2851-2859, 2004
60. Matsubara S, Ueda Y, Takahashi H, Nagai T, Kuwata T, Muto S, Yamaguchi T, Takizawa T, Suzuki M: Pregnancy complicated with Alport syndrome: a good obstetric outcome and failure to diagnose an infant born to a mother with Alport syndrome by umbilical cord immunofluorescence staining. J Obstet Gynaecol Res 35: 1109-1114, 2009
61. Hood JC, Savige J, Hendtlass A, Kleppel MM, Huxtable CR, Robinson WF: Bull terrier hereditary nephritis: a model for autosomal dominant Alport syndrome. Kidney Int 47: 758-765, 1995
62. Ierino FL, Kanellis J: Thin basement membrane nephropathy and renal transplantation. Semin Nephrol 25: 184-187, 2005 (Pubitemid 40692803)
63. Haas M: Alport syndrome and thin glomerular basement membrane nephropathy: A practical approach to diagnosis. Arch Pathol Lab Med 133: 224-232, 2009
64. Pettersson E, Törnroth T, Wieslander J: Abnormally thin glomerular basement membrane and the Goodpasture epitope. Clin Nephrol 33: 105-109, 1990 (Pubitemid 20103997)
65. Jefferson JA, Lemmink HH, Hughes AE, Hill CM, Smeets HJ, Doherty CC, Maxwell AP: Autosomal dominant Alport syndrome linked to the type IV collage alpha 3 and alpha 4 genes (COL4A3 and COL4A4). Nephrol Dial Transplant 12: 1595-1599, 1997 (Pubitemid 27346283)
66. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric,non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
67. Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia: ACE inhibitors to prevent end-stage renal disease:When to start andwhy possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am SocNephrol 12: 2832-2837, 2001 (Pubitemid 33115432)
68. Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M: Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63: 438-446, 2003 (Pubitemid 36126790)
69. Sakai K, Muramatsu M, Ogiwara H, Kawamura T, Arai K, Aikawa A, Ohara T, Mizuiri S, Joh K, Naito I, Hasegawa A: Living related kidney transplantation in a patient with autosomal-recessive Alport syndrome. Clin Transplant 17[Suppl 10]: 4-8, 2003 (Pubitemid 36958170)